iohexol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
iodine-containing contrast media	1461	66108-95-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iohexol	An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. Molecular weight: 821.14 Formula: C19H26I3N3O9 CLOGP: -2.44 LIPINSKI: 3 HAC: 12 HDO: 8 TPSA: 199.89 ALOGS: -3.01 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

iohexol

An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Molecular weight: 821.14
Formula: C19H26I3N3O9
CLOGP: -2.44
LIPINSKI: 3
HAC: 12
HDO: 8
TPSA: 199.89
ALOGS: -3.01
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	95 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4597.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	2 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.50 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.80 mg/mL	Bocci G, Oprea TI, Benet LZ
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 8 of 8 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 26, 1985	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	890.30	31.92	401	6187	165401	63317033
Sneezing	567.36	31.92	163	6425	18055	63464379
Pruritus	454.11	31.92	340	6248	361113	63121321
Contrast media reaction	442.99	31.92	80	6508	1045	63481389
Erythema	311.93	31.92	205	6383	175546	63306888
Extravasation	286.88	31.92	63	6525	2309	63480125
Throat irritation	232.13	31.92	101	6487	37546	63444888
Contrast media allergy	231.54	31.92	53	6535	2348	63480086
Throat tightness	177.27	31.92	74	6514	24813	63457621
Dyspnoea	140.44	31.92	247	6341	661066	62821368

Showing 1 to 10 of 40 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	584.83	28.14	245	4681	62132	34889873
Sneezing	402.43	28.14	102	4824	5140	34946865
Contrast media reaction	325.51	28.14	63	4863	883	34951122
Pruritus	260.66	28.14	190	4736	141791	34810214
Erythema	224.59	28.14	145	4781	88635	34863370
Contrast media allergy	196.86	28.14	37	4889	438	34951567
Extravasation	196.63	28.14	47	4879	1843	34950162
Anaphylactic reaction	160.24	28.14	82	4844	32219	34919786
Rash maculo-papular	106.67	28.14	60	4866	28391	34923614
Anaphylactic shock	95.33	28.14	46	4880	15895	34936110

Showing 1 to 10 of 28 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urticaria	1216.54	26.77	566	10635	184635	79548552
Sneezing	863.57	26.77	246	10955	19437	79713750
Contrast media reaction	688.93	26.77	134	11067	1936	79731251
Pruritus	641.84	26.77	490	10711	394158	79339029
Erythema	458.38	26.77	320	10881	222970	79510217
Extravasation	441.40	26.77	103	11098	3647	79729540
Contrast media allergy	359.66	26.77	81	11120	2441	79730746
Throat irritation	266.25	26.77	125	11076	40821	79692366
Anaphylactic reaction	247.04	26.77	151	11050	83592	79649595
Throat tightness	218.55	26.77	97	11104	27810	79705377

Showing 1 to 10 of 67 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	V08AB02	VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:37338	contrast media
CHEBI has role	CHEBI:78298	environmental contaminants
FDA EPC	N0000180185	Radiographic Contrast Agent
FDA MoA	N0000010258	X-Ray Contrast Activity
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.73	acidic
pKa2	11.33	acidic
pKa3	12.2	acidic
pKa4	13.65	acidic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
000673	NDDF
109218004	SNOMEDCT_US
3730	PUBCHEM_CID
395751002	SNOMEDCT_US
4018251	VUID
4018251	VANDF
4419T9MX03	UNII
4848	INN_ID
4904	MMSL
5956	RXNORM

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1401	INJECTION, SOLUTION	140 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1411	INJECTION, SOLUTION	180 mg	ORAL	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections
OMNIPAQUE	HUMAN PRESCRIPTION DRUG LABEL	1	0407-1412	INJECTION, SOLUTION	240 mg	INTRAVENOUS	NDA	28 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next